Q-Line Biotech Board of Directors
Get the latest insights into the leadership at Q-Line Biotech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Saurabh Garg | Chairman & Managing Director |
| Kuldeep Chowdhry | Whole Time Director |
| Ajay Kumar Mahanty | Whole Time Director |
| Yethadka Subraya Prabhakara | Whole Time Director |
| Abhay Agrawal | Non Executive Director |
| Amita Garg | Non Executive Director |
| Ayush Garg | Non Executive Director |
| Jai Prakash Singh | Non Executive Independent Director |
| Pravir Kumar | Non Executive Independent Director |
| Rohit Nandan | Non Executive Independent Director |
| Abhishek Mishra | Non Executive Independent Director |
| Akhand Pratap Singh | Company Secretary & Compliance Officer |
Q-Line Biotech FAQs
The board at Q-Line Biotech consists of experienced professionals, including Saurabh Garg, Kuldeep Chowdhry, and others, overseeing the company’s strategic and corporate governance.
Directors at Q-Line Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Saurabh Garg is the current chairman at Q-Line Biotech.
Executive directors at Q-Line Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Q-Line Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Q-Line Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
